TMEM106A mediates atherosclerosis progression through macrophage-centered immune responses and chemokine signaling
TMEM106A contributes to AS progression by modulating macrophage-mediated immune responses and chemokine signaling, as validated in experimental models. These findings support its potential as a clinically relevant biomarker and promising therapeutic target for AS intervention.
Authors
- Qingyun Zhang (ORCID: https://orcid.org/0000-0001-5439-4517)
- Lun Jia (ORCID: https://orcid.org/0000-0002-2091-3216)
- Yin Huang (ORCID: https://orcid.org/0000-0001-6913-4670)
- Zhen Fang (ORCID: https://orcid.org/0000-0002-7073-8997)
- Menglong Gao
- Zhenhua Li (ORCID: https://orcid.org/0000-0001-9751-0864)
- Yunbo Zhao
- Xingbang Liu (ORCID: https://orcid.org/0000-0002-0918-1923)
Institutions
- Weifang Medical University (CN)
- Sun Yat-sen University (CN)
- Weifang People's Hospital (CN)
- Fifth Affiliated Hospital of Sun Yat-sen University (CN)
- Heze Municipal Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1681645
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00